Cleo Diagnostics (ASX:COV) Debt-to-EBITDA : 0.00 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cleo Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Cleo Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Cleo Diagnostics's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-5.11 Mil. Cleo Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cleo Diagnostics's Debt-to-EBITDA or its related term are showing as below:

ASX:COV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.02 Med: -1.02 Max: -0.43
Current: -0.43

During the past 1 years, the highest Debt-to-EBITDA Ratio of Cleo Diagnostics was -0.43. The lowest was -1.02. And the median was -1.02.

ASX:COV's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs ASX:COV: -0.43

Cleo Diagnostics Debt-to-EBITDA Historical Data

The historical data trend for Cleo Diagnostics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Debt-to-EBITDA Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Debt-to-EBITDA

-1.02

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Debt-to-EBITDA	-1.89	-0.68	-

Competitive Comparison of Cleo Diagnostics's Debt-to-EBITDA

For the Medical Devices subindustry, Cleo Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Debt-to-EBITDA falls into.

Cleo Diagnostics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cleo Diagnostics's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.6	+	0)	/	-1.575
	=	-1.02

Cleo Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-5.11
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Cleo Diagnostics (ASX:COV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cleo Diagnostics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines